BCR Signaling Inhibitors: an Overview of Toxicities Associated with Ibrutinib and Idelalisib in Patients with Chronic Lymphocytic Leukemia

The B-cell receptor (BCR) signaling inhibitors ibrutinib and idelalisib are revolutionizing the treatment of chronic lymphocytic leukemia (CLL) and other B-cell malignancies. These oral agents, both alone and in combination with other drugs, have shown remarkable clinical activity in relapsed or ref...

Descripción completa

Detalles Bibliográficos
Autores principales: Falchi, Lorenzo, Baron, Jessica M., Orlikowski, Carrie Anne, Ferrajoli, Alessandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Università Cattolica del Sacro Cuore 2016
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4771137/
https://www.ncbi.nlm.nih.gov/pubmed/26977270
http://dx.doi.org/10.4084/MJHID.2016.011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4771137/
https://www.ncbi.nlm.nih.gov/pubmed/26977270
http://dx.doi.org/10.4084/MJHID.2016.011

Ejemplares similares